All News
ACR Best Abstracts - Day 1
The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).
Read Article
JAK and TYK-2 inhibitors and indications in SpA:
● Tofacitinib ➣ Pan JAKi (AS, PsA)
● Baricitinib ➣ JAK1,2
● Upadacitinib ➣ JAK1 (AxSpA, PsA)
● Deucravacitinib ➣ TYK2 (PsA)
Carol Langford, Year in Review #ACR22 @RheumNow https://t.co/EMLEvptySS
Dr. Antoni Chan synovialjoints ( View Tweet)
Differences between #uveitis pattern in AS vs. PsA and IBD 👇
This is always asked to our rheum fellows during Kelley's hour 🤓
#ACR22 @RheumNow @rheumarhyme @trishiemd @RheumaRamblings @RheumaRambolMD https://t.co/gWxQ9xdb06
sheila RHEUMarampa ( View Tweet)
Across 9 trials of Upadacitinib in RA, PsA and AS, 40%–50% of patients had ≥ 2 CV risk factors, ≥ 65 years 6%–23%. Rates of adjudicated MACE and VTE with UPA were infrequent, consistent with background rates in RA, PsA, and AS Abst 0510 https://t.co/HDkQ6ELnAy #ACR22 @RheumNow https://t.co/SRJYdFFNIQ
Dr. Antoni Chan synovialjoints ( View Tweet)
Abstr 0383 evaluated the use of previously developed AI algorithm to detect sacroiliitis in a new axSpA cohort. The neural network achieved
-Sensitivity 82%; specificity 81%
-PPV 0.89; NPV 0.70
https://t.co/PDSsiMIQUc
@RheumNow #ACR22 #AI #MachineLearning #AxSpA https://t.co/mXUHUowGhQ
Akhil Sood MD AkhilSoodMD ( View Tweet)
SELECT-AXIS 2 subgroup analysis. UPA demonstrated improved efficacy vs PBO at Wk 14 across all evaluated subgroups of pts with bDMARD-IR AS. No new safety signals. @XBaraliakos et al, Abs 0414 #ACR22 https://t.co/lTfm68XlEY https://t.co/PaWdrOljMO
Dr. Rachel Tate uptoTate ( View Tweet)
Interesting data on TNFi use in ankylosing spondylitis.
Early TNFi use, compared to no TNFi associated with higher CVD, stroke and MACE.
@rheum_cat any thought on why? and why there were so many non-TNFi users (15k vs. 2k)?
Abs#0415 @RheumNow #ACR22 https://t.co/PVkt8gPHFW
Robert B Chao, MD doctorRBC ( View Tweet)
@rheum_cat et al Abs 0415 TNFi initiation early in AS dz course (compared to no initiation) showed higher risk of incident CVD, stroke & MACE individually! Residual confounding by indication cannot be excluded. Were TNFi tx pts sicker? #ACR22 @RheumNow https://t.co/ERoDhS2yOY https://t.co/8tto5AIUSP
Dr. Rachel Tate uptoTate ( View Tweet)
Can I use BASDAI to asses disease in #pregnant AS patients?
Abstract #0374 #ACR22 @RheumNow; 50 women
🫃Back pain and fatigue beyond 4.5 months = not reliable
🫃BASDAI in 3rd trimester = not reliable
🫃Morning stiffness remains reliable marker of disease in pregnancy
Catherine Sims, MD DrCassySims ( View Tweet)
Wanna know more about SpA in female patients? Just ask @Sineadm15! Check out my interview with her at #ACR22 @RheumNow https://t.co/NSM4pJeb6g
Dr. Rachel Tate uptoTate ( View Tweet)
👁 What causes worse outcomes in our SpA uveitis pts? 👁
🚬 smoking Hx
🦴 ax + peripheral disease
✏️ BASDAI >4
👩🔬 HLA B27 +ve
🙋♀️ females
🧪CRP ⬆️
👁 bilat eye involvement
Abst#0373
#ACR22 @RheumNow
Patricia Harkins DrTrishHarkins ( View Tweet)
IL-17A/F inhibition with Bimekizumab in active nr-axSpA Wk 16 ASAS40 vs PBO
• Rapid improvement 47.7 vs 21.4%
• TNF naive 46.6 vs 22.9%
• TNFIR 60 vs 11.8%
• Wk 24 >50% ASDAS <2.1
• Improved MRI
• Serious TEAE 0.4%
Deodhar Abs0544 https://t.co/q9dbQP5oLD #ACR22 @RheumNow https://t.co/VCJgo56JrA
Dr. Antoni Chan synovialjoints ( View Tweet)
Abs 0412 by @Spondy_MD et al at #ACR22: BKZ tx showed meaningful improvements in physical function and HRQoL in nr-axSpA and AS pts with consistent responses. @RheumNow https://t.co/diGqpQKfpS https://t.co/1pdGi47IJM
Dr. Rachel Tate uptoTate ( View Tweet)
Another study showing treatment withdrawal does not work.
Golimumab withdrawal in nr-axSpA is inferior to continued treatment or tapered treatment, leading to more disease flares.
Abs#0545 @RheumNow #ACR22 https://t.co/CBRnVdxXVo
Robert B Chao, MD doctorRBC ( View Tweet)
2022 ASAS-EULAR recommendation lit review in Abs 0413 at #ACR22 shows new evidence on education & exercise and confirms efficacy in axSpA. Tofa, UPA, FIL have shown efficacy in r-axSpA. @RheumNow https://t.co/8E9RZQ8Gz4 https://t.co/5QPO5eddFH
Dr. Rachel Tate uptoTate ( View Tweet)
Interesting findings from Abs 0417 - when early axSpA is defined by duration of symptoms, only nr-axSpA tx w/ bDMARDs may lead to better outcomes vs early or established axSpA. #ACR22 @RheumNow https://t.co/8aGdyJRvv1 https://t.co/chAEGPicPd
Dr. Rachel Tate uptoTate ( View Tweet)
NSAIDs plus TNFi (celecoxib and golimumab) therapy in ankylosing spondylitis did not show significant decrease in radiographic progression compared to TNFi monotherapy.
*Numerical reduction in syndesmophytes 11% vs. 25%
Abs#0546
@RheumNow #ACR22
#ACRBest https://t.co/pG5F3xdsh9
Robert B Chao, MD doctorRBC ( View Tweet)
Abs 0419 SELECT-AXIS 2, UPA improved outcomes vs PBO in nr-axSpA pts across all BL inflammation subgroups; greatest benefit obs in pts with both elevated CRP and inflammation on baseline MRI. #ACR22 @RheumNow https://t.co/opaFwXgcvU https://t.co/o27ULcL8Ip
Dr. Rachel Tate uptoTate ( View Tweet)
#Abstr 0545 GO-BACK Trial
Continue vs Withdrawal of GOL in nr-axSpA with inactive disease
- Full tx withdrawal associated w/ dx flare
- Re-treatment -->rapid clinical response after flare
- qMonthly tx --> higher rates of disease activity improvement
@RheumNow #ACR22 https://t.co/Z3bhA9D4RQ
Akhil Sood MD AkhilSoodMD ( View Tweet)
#ACR22 Abs 0408 @philipcrobinson et al, nr-axSpA pts achieving long-term clinical outcomes w/ CZP tx after 1 yr were generally sustained over 3 yrs across MRI+/CRP+, MRI−/CRP+ and MRI+/CRP− subgroups; ASDAS-MI numerically highest in MRI+/CRP+. @RheumNow https://t.co/cjpp2qCN4O https://t.co/G2YjF6ubUf
Dr. Rachel Tate uptoTate ( View Tweet)
